These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 30536402)

  • 21. Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.
    Gopal S; Mikulskis A; Gold R; Fox RJ; Dawson KT; Amaravadi L
    Mult Scler; 2017 Dec; 23(14):1875-1883. PubMed ID: 28156185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different Fumaric Acid Esters Elicit Distinct Pharmacologic Responses.
    Wipke BT; Hoepner R; Strassburger-Krogias K; Thomas AM; Gianni D; Szak S; Brennan MS; Pistor M; Gold R; Chan A; Scannevin RH
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33468560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insight into the mechanism of action of dimethyl fumarate in multiple sclerosis.
    Yadav SK; Soin D; Ito K; Dhib-Jalbut S
    J Mol Med (Berl); 2019 Apr; 97(4):463-472. PubMed ID: 30820593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Delayed lymphocyte re-population following discontinuation of dimethyl fumarate and after switching to other disease modifying drug therapies.
    Khatri BO; Tarima SS; Essig B; Sesing J; Olapo T
    Mult Scler Relat Disord; 2017 Nov; 18():60-64. PubMed ID: 29141823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxycarboxylic Acid Receptor 2, a Pleiotropically Linked Receptor for the Multiple Sclerosis Drug, Monomethyl Fumarate. Possible Implications for the Inflammatory Response.
    Parodi B; Sanna A; Cedola A; Uccelli A; Kerlero de Rosbo N
    Front Immunol; 2021; 12():655212. PubMed ID: 34084164
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dimethyl fumarate induced migrating polyarthralgias.
    Villedon de Naide M; Moisset X; Soubrier M
    Joint Bone Spine; 2019 May; 86(3):399-400. PubMed ID: 30081200
    [No Abstract]   [Full Text] [Related]  

  • 27. Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile.
    Medina S; Villarrubia N; Sainz de la Maza S; Lifante J; Costa-Frossard L; Roldán E; Picón C; Álvarez-Cermeño JC; Villar LM
    Mult Scler; 2018 Sep; 24(10):1317-1327. PubMed ID: 28653862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diroximel fumarate to treat multiple sclerosis.
    Wang Y; Bhargava P
    Drugs Today (Barc); 2020 Jul; 56(7):431-437. PubMed ID: 32648853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monomethyl fumarate treatment impairs maturation of human myeloid dendritic cells and their ability to activate T cells.
    Mazzola MA; Raheja R; Regev K; Beynon V; von Glehn F; Paul A; Pierre I; Kivisakk P; Weiner HL; Gandhi R
    Mult Scler; 2019 Jan; 25(1):63-71. PubMed ID: 29106333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapsing-Remitting Multiple Sclerosis Is Characterized by a T Follicular Cell Pro-Inflammatory Shift, Reverted by Dimethyl Fumarate Treatment.
    Cunill V; Massot M; Clemente A; Calles C; Andreu V; Núñez V; López-Gómez A; Díaz RM; Jiménez MLR; Pons J; Vives-Bauzà C; Ferrer JM
    Front Immunol; 2018; 9():1097. PubMed ID: 29896193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythema nodosum in a patient with multiple sclerosis on dimethyl fumarate.
    Algahtani H; Shirah B; Marghalani S; Algarni A
    Mult Scler Relat Disord; 2019 Feb; 28():155-158. PubMed ID: 30597324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dimethyl Fumarate Therapy Significantly Improves the Responsiveness of T Cells in Multiple Sclerosis Patients for Immunoregulation by Regulatory T Cells.
    Schlöder J; Berges C; Luessi F; Jonuleit H
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.
    Baharnoori M; Gonzalez CT; Chua A; Diaz-Cruz C; Healy BC; Stankiewicz J; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2018 Feb; 20():51-57. PubMed ID: 29304497
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered adipokine levels are associated with dimethyl fumarate treatment in multiple sclerosis patients.
    Baharnoori M; Wilson R; Saxena S; Gonzalez CT; Sotiropoulos MG; Keyhanian K; Healy BC; Chitnis T
    Mult Scler Relat Disord; 2021 Nov; 56():103311. PubMed ID: 34655958
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of action of three newly registered drugs for multiple sclerosis treatment.
    Kasarełło K; Cudnoch-Jędrzejewska A; Członkowski A; Mirowska-Guzel D
    Pharmacol Rep; 2017 Aug; 69(4):702-708. PubMed ID: 28550802
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe multiple sclerosis reactivation during prolonged lymphopenia after dimethyl fumarate discontinuation.
    Zecca C; Antozzi CG; Torri Clerici V; Ferrazzini M; Mantegazza RE; Rossi S; Gobbi C
    Acta Neurol Scand; 2018 Jun; 137(6):623-625. PubMed ID: 29205270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study.
    Marastoni D; Buriani A; Pisani AI; Crescenzo F; Zuco C; Fortinguerra S; Sorrenti V; Marenda B; Romualdi C; Magliozzi R; Monaco S; Calabrese M
    Front Immunol; 2019; 10():1666. PubMed ID: 31379857
    [No Abstract]   [Full Text] [Related]  

  • 39. Dimethyl fumarate-related immune and transcriptional signature is associated with clinical response in multiple sclerosis-treated patients.
    Sánchez-Sanz A; García-Martín S; Sabín-Muñoz J; Moreno-Torres I; Elvira V; Al-Shahrour F; García-Grande A; Ramil E; Rodríguez-De la Fuente O; Brea-Álvarez B; García-Hernández R; García-Merino A; Sánchez-López AJ
    Front Immunol; 2023; 14():1209923. PubMed ID: 37483622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.
    Li R; Rezk A; Ghadiri M; Luessi F; Zipp F; Li H; Giacomini PS; Antel J; Bar-Or A
    J Immunol; 2017 Jan; 198(2):691-698. PubMed ID: 27974457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.